Get started
Author

Luca Rigodanza

Observed name: L. Rigodanza
ORCID: 0009-0006-6972-6450
Observed ORCID: 0009-0006-6972-6450
OpenAlex ID: A5077121988
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025 · Angela Consagra, Luca Lanino, et al. · HemaSphere · 16
PDF
Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents
2024 · Marco G. Raddi, Sara Bencini, et al. · Blood Cancer Journal · 9
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score
2025 · Marco G. Raddi, Sophie Park, et al. · Blood · 7
Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms
2023 · Marco Gabriele Raddi, Angela Consagra, et al. · Blood · 3
Improved Overall Survival Among Luspatercept Responders and Predictors of Response
2023 · Angela Consagra, Luca Lanino, et al. · Blood · 2
Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine
2023 · Valeria Santini, Cristina Amato, et al. · Blood · 1
PDF
MDS-462 Response to Erythropoiesis-Stimulating Agent Therapy in IPSS-R Lower Risk Myelodysplastic Syndrome Patients Restratified According to IPSS-M
2023 · Luca Rigodanza, Angela Consagra, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
PDF
The Combination of Decitabine Plus Venetoclax Is an Active Salvage Therapy for AML Post HR-MDS Progressed during Treatment with Azacitidine Based Regimens
2022 · Angela Consagra, Alessandro Sanna, et al. · Blood · 1
CO33 | Variant-specific prognostic impact of SRSF2 p95 mutations in ASXL1-mutated myelodysplastic syndromes
2026 · Luca Rigodanza · Haematologica
PDF
From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS
2025 · Sven De Pourcq, Giorgio Mattiuz, et al. · Blood
Plenary Session 06: Treatment Low Risk Mds (part 1)
2025 · Marco Raddi, Sara Bencini, et al. · Leukemia Research
Treatment - Current Treatment Options - Higher Risk Mds
2025 · Valeria Santini, Sven Depourcq, et al. · Leukemia Research
POSTER: MDS-560 Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025 · Angela Consagra, Luca Rigodanza, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-693 Distinct Molecular Subtypes in DDX41-Mutated MDS: Germline vs Somatic Landscapes
2025 · Gloria Andreossi, Giorgio Mattiuz, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-560: Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025 · Angela Consagra, Luca Rigodanza, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-693: Distinct Molecular Subtypes in DDX41-Mutated MDS: Germline vs Somatic Landscapes
2025 · Gloria Andreossi, Giorgio Mattiuz, et al. · Clinical Lymphoma Myeloma & Leukemia
Exploring the Unseen Effects of Epigenetic Age Acceleration in Low-Risk MDS: Associations with Unique Cytokine Profiles
2024 · Sven De Pourcq, Elena Tofacchi, et al. · Blood
PDF
MDS-679 TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status
2024 · Luca Rigodanza, Gloria Andreossi, et al. · Clinical Lymphoma Myeloma & Leukemia
TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status
2024 · Luca Rigodanza, Gloria Andreossi, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-462 Response to Erythropoiesis-Stimulating Agent Therapy in IPSS-R Lower Risk Myelodysplastic Syndrome Patients Restratified According to IPSS-M
2023 · Luca Rigodanza, Angela Consagra, et al. · Clinical Lymphoma Myeloma & Leukemia
Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WITH RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS
2023 · M.G. Raddi, A. Consagra, et al. · Leukemia Research
Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine
2022 · Valeria Santini, Cristina Amato, et al. · Blood
Characteristics and Distribution of Erythroid Progenitors and Precursors Correlate with Erythropoiesis Stimulating Agents (ESAs) Response in Lower Risk Myelodysplastic Syndromes
2022 · Marco Gabriele Gabriele Raddi, Sara Bencini, et al. · Blood
Works count: 23
Citation count: 40
H-index: 3
I10-index: 1
Year
Topic
Type